+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID00801489

Evaluating a Combination of Fludarabine, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin for Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Led by M.D. Anderson Cancer Center · Updated on 2026-10-07

270

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a combination of drugs including fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochloride to study their effects and side effects in patients with newly diagnosed acute myeloid leukemia AML or high-risk myelodysplastic syndrome MDS. This phase II trial aims to assess the safety of this drug regimen and the rates of complete remission in patients with specific AML subtypes associated with inv16 or t821 chromosomal abnormalities. The study also explores the use of quantitative PCR to detect relapse and the long-term survival of patients in remission. Participants receive remission induction therapy consisting of filgrastim-sndz injections daily starting one day before chemotherapy and continuing until blood counts recover. They also receive intravenous fludarabine phosphate and cytarabine over five days, with gemtuzumab ozogamicin given on the first day. If remission is not achieved, induction may be repeated. Post-remission therapy involves additional courses combining these drugs with idarubicin hydrochloride administered intravenously on specific days. Treatment cycles repeat every 4 to 6 weeks for up to six courses unless disease progresses or toxicity occurs. For some patients, especially older adults or those with complications, decitabine may be given intravenously daily for five days up to 12 courses after consultation. During the study, participants undergo regular assessments including blood counts and molecular testing using quantitative PCR to monitor disease status and detect relapse. After completing treatment, patients are followed every six months for two years to observe long-term outcomes. The main outcomes measured are complete remission rates and toxicity over a two-year period. This comprehensive monitoring helps evaluate the treatment effects and patient safety throughout the trial duration.

CONDITIONS

Brief Title

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Research Team

J

Jayastu Senapati

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here